29,950 Shares in Assembly Biosciences, Inc. $ASMB Bought by Ellsworth Advisors LLC

Ellsworth Advisors LLC purchased a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 3rd quarter, HoldingsChannel reports. The fund purchased 29,950 shares of the biopharmaceutical company’s stock, valued at approximately $852,000.

Several other institutional investors have also recently made changes to their positions in ASMB. Palumbo Wealth Management LLC grew its stake in shares of Assembly Biosciences by 3.8% in the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 681 shares during the period. Geode Capital Management LLC boosted its holdings in Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after acquiring an additional 3,312 shares in the last quarter. Acadian Asset Management LLC grew its stake in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares during the period. Finally, American Century Companies Inc. bought a new stake in shares of Assembly Biosciences during the first quarter valued at approximately $113,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ASMB shares. Citizens Jmp assumed coverage on Assembly Biosciences in a report on Wednesday, September 24th. They issued an “outperform” rating and a $38.00 target price on the stock. Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Thursday, November 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. Finally, JMP Securities started coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They issued a “market outperform” rating and a $38.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $33.62 on Friday. The firm has a 50-day moving average of $33.81 and a 200-day moving average of $25.96. Assembly Biosciences, Inc. has a one year low of $7.75 and a one year high of $39.71. The company has a market cap of $531.87 million, a P/E ratio of -7.02 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $7.46 million. Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%. As a group, research analysts expect that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.